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Purpose: Mindfulness interventions have been shown to treat depressive symptoms
and improve quality of life in patients with several chronic diseases, including multiple
sclerosis, but to date most evaluation of the effectiveness of mindfulness interventions
in multiple sclerosis have used patients receiving standard care as the control group.
Hence we decided to evaluate the effectiveness of a group-based body-affective
mindfulness intervention by comparing it with a psycho-educational intervention, by
means of a randomized controlled clinical trial. The outcome variables (i.e., depression,
anxiety, perceived stress, illness perception, fatigue and quality of life) were evaluated at
the end of the interventions (T1) and after a further 6 months (T2).
Methods: Of 90 multiple sclerosis patients with depressive symptoms (Beck Depression
Inventory-II score greater than 13) who were randomized, 71 completed the intervention
(mindfulness group n = 36; psycho-educational group n = 35). The data were analyzed
with GLM repeated-measures ANOVA followed by pairwise comparisons.
Results: Per-protocol analysis revealed a time by group interaction on Beck Depression
Inventory-II score, with the mindfulness intervention producing a greater reduction in
score than the psycho-educational intervention, both at T1 and at T2. Furthermore,
the mindfulness intervention improved patients’ quality of life and illness perception
at T1 relative to the baseline and these improvements were maintained at the follow-
up assessment (T2). Lastly, both interventions were similarly effective in reducing
anxiety and perceived stress; these reductions were maintained at T2. A whole-sample
intention-to-treat (ITT) analysis broadly confirmed the effectiveness of the mindfulness
intervention.
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Conclusion: In conclusion, these results provide methodologically robust evidence
that in multiple sclerosis patients with depressive symptoms mindfulness interventions
improve symptoms of depression and anxiety and perceived stress, modulate illness
representation and enhance quality of life and that the benefits are maintained for at
least 6 months.
Trial registration: the study was registered in the ClinicalTrials.gov registry
(NCT02611401).
Keywords: multiple sclerosis, depression, mindfulness, mindfulness based intervention, quality of life,
psycho-education
INTRODUCTION
Multiple sclerosis (MS) is a chronic, demyelinating disease and
onset usually occurs at a young age. People with MS have to deal
not only with many debilitating and unpredictable symptoms
and with the loss of function and the consequent disability, but
also with the unpredictability of the disease and the uncertain
prognosis. This imposes a significant emotional burden and has a
severe impact on psychosocial functioning.
Previous studies focusing on the psychosocial impact of MS
have shown that depression, anxiety and reduced quality of life
are prevalent (Wallin et al., 2006; Beiske et al., 2008; Byatt et al.,
2011; Feinstein, 2011; Moore et al., 2012; Ostacoli et al., 2013).
In particular, depression seems to be more prevalent in MS
than in other chronic neurological diseases (Wallin et al., 2006)
and three times more prevalent than in the general population
(Feinstein, 2011). There are reports that depression affects from
15 to 47% of MS patients (Chwastiak et al., 2002; Siegert and
Abernethy, 2005), with an estimated lifetime prevalence of 50%
in people with MS (Sadovnick et al., 1991). The prevalence of
comorbid depression in MS seems to worsen over time, although
it is high even at the time of MS diagnosis (Marrie et al.,
2015). The reasons for the comorbidity of MS and depression
are many and complex. Depression could be considered a
reaction to the unpredictability and chronicity of the disease,
but it is also possible that MS-related biological processes such
as immunological and inflammatory pathways, or psychosocial
risk factors like inadequate coping or insufficient social support
could predispose MS patients to depression (Feinstein, 2011;
Feinstein et al., 2014; Boeschoten et al., 2017). Depression has
a negative impact on the course of MS; as well as increasing
the symptom burden and negatively influencing adherence to
treatment it has direct pathophysiological effects on immunity
(Mohr et al., 1997; Boeschoten et al., 2017). It has also been
shown that depression in MS is strongly related to lower quality
of life, cognitive dysfunction, elevated suicide risk and fatigue
(Fruehwald et al., 2001; Brown et al., 2009; Patrick et al., 2009;
Fiest et al., 2016; Boeschoten et al., 2017), which is one of
the most commonly reported and debilitating symptoms of
MS (Wallin et al., 2006). Nevertheless, affective disorders in
MS are still under-recognized and under-treated by clinicians
(Goldman Consensus Group, 2005). For these reasons the
American Academy of Neurology formulated evidence-based
recommendations for screening, diagnosis and treatment of
psychiatric disorders in MS (Minden et al., 2014), recommending
further research on the utility of treatments shown to be effective
in other clinical populations.
Psychopharmacological treatments, such as serotonin selective
reuptake inhibitors (SSRI), are quite effective as treatments for
depression in MS, but they have prominent side effects and the
drop-out rate is high (Koch et al., 2011). In contrast psychological
treatments have been shown to have beneficial effects on both
depression and quality of life in patients with MS. In particular,
cognitive behavioral therapy (CBT) has been shown to have a
moderate effect on depression (Thomas et al., 2006; Fiest et al.,
2016). Feinstein and colleagues (Feinstein, 2011; Feinstein et al.,
2014) have noted that publicly funded treatments for depression
in MS patients must take account of resource constraints and
that it is therefore crucial to identify brief, yet cost-effective
interventions that can reduce depressive symptoms and the
psychological burden of MS, in order to improve patients’ quality
of life (Feinstein et al., 2014).
Mindfulness-based interventions (MBIs) are psychological
treatments that meet the need for brevity and cost-effectiveness.
They have been shown to be effective in patients with several
diseases, including chronic pain, cancer and fibromyalgia
(Hofmann et al., 2010; Crowe et al., 2016). MBIs influence
emotion regulation, using awareness of the present moment and
a non-judgmental, accepting attitude, to disrupting dysfunctional
tendencies to avoid or over-engage with one’s disturbing physical
sensations, emotions and thoughts. MBIs have been shown
to have large beneficial effects on depression in patients with
depressive disorders and to be effective in preventing relapse
(Hofmann et al., 2010; Piet and Hougaard, 2011; Kuyken
et al., 2016). Furthermore, MBIs have been shown to produce
a moderate reduction in depressive symptoms associated with
medical conditions (Hofmann et al., 2010; Crowe et al.,
2016). These results suggest that MBIs could address processes
underlying multiple disorders by changing several emotional and
cognitive dimensions (Hofmann et al., 2010; Feinstein, 2011).
Mindfulness can lead patients to relate to their physical and
psychological symptoms in a different way, with a positive effect
on coping strategies and adaptation to the disease (Feinstein,
2011).
Recent systematic reviews have indicated that MBIs are
effective in MS patients (Simpson et al., 2014; Levin et al., 2014;
San José et al., 2016). Both a review including only controlled
trial (Simpson et al., 2014) and a review using a less restrictive
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criterion of effectiveness (Levin et al., 2014) concluded that MBIs
can improve MS patients’ quality of life and mental health, and
improve ability to cope with some of the physical symptoms,
such as fatigue and pain. Senders et al. (2014) confirmed that
in MS, trait mindfulness is related to lower psychological stress,
a more constructive coping profile, increased resilience and
higher quality of life. Bogosian et al. (2015) and Schirda et al.
(2015) corroborated these results, suggesting that mindfulness
could improve MS patients’ quality of life by reducing emotion
dysregulation, especially in patients with more symptoms of
depression. Moreover, MBIs were shown to have a low overall
attrition rate and no side-effects and patients reported high
goal satisfaction (Grossman et al., 2010; Simpson et al., 2014).
However, systematic reviews have also highlighted that most of
the data demonstrating the effectiveness of MBIs were obtained
in non-controlled trials or in comparison with standard care
and argued that there is a need for more rigorous clinical trials
comparing MBI with active control groups (Levin et al., 2014;
Simpson et al., 2014).
We therefore conducted a randomized controlled trial
comparing a MBI with an active control intervention in MS
patients with depressive symptoms. We evaluated the effects of
a group-based body-affective mindfulness (BAM) intervention
on depressive symptoms in patients with MS at the end of
the intervention and 6 months later. We also evaluated the
effects of the BAM intervention on quality of life, illness
perception, symptoms of anxiety, perceived stress and fatigue. We
hypothesized that the BAM intervention would be more effective
than the control intervention, a psycho-educational intervention.
The final aim of this study was to evaluate the effectiveness of the
BAM intervention in treating depression and related symptoms
and improving quality of life in caregivers. As the caregivers
of patients with MS must deal with the stress and difficulties
associated with management of a chronic disabling disease we
expected that they would also benefit from the treatment.
MATERIALS AND METHODS
Design
We carried out a randomized controlled clinical trial (RCT).
MS patients with depressive symptoms were randomly allocated
to the BAM group or the active control group, which received
a psycho-educational intervention (PEI). The required sample
size was calculated to be 82, based on α = 0.05, power = 0.80
and a medium effect size (0.25) with respect to depressive
symptoms. The Medical Ethics Committee of San Luigi Gonzaga
University Hospital approved the protocol and the study was
registered in the ClinicalTrials.gov registry (NCT02611401). All
the participants gave written, informed consent.
Participants and Procedures
Participants were enrolled at the CReSM Unit of the San Luigi
University Hospital of Orbassano (Italy), the regional referral
center for MS.
Multiple sclerosis patients that presented to the CReSM for a
routine visit, a blood test or an infusion therapy were invited to
participate and complete the Beck Depression Inventory-II (BDI-
II) on a consecutive basis. Patients with a BDI-II score greater
than 13 who met the other criteria for participation were included
in the study.
As previously described (Carletto et al., 2016), the inclusion
criteria were: (1) definite diagnosis of MS (Mc Donald Criteria)
(Polman et al., 2011) made or confirmed at the CReSM Unit
at least 6 months prior the beginning of the study; (2) age
between 18 and 65 years; (3) no evidence of clinical relapse and
no worsening of score on the Expanded Disability Status Scale
(EDSS) in the last 3 months; (4) an EDSS score lower than
6.5; (5) fluent Italian speaker; (6) legal capacity to consent to
the treatment; (7) willingness to abstain from or to suspend all
other psychological treatment; (8) suspension of all psychotropic
medication at least 1 month before the start of the intervention
or maintenance at baseline level throughout the study. The
exclusion criteria were: (1) current serious psychological or
psychiatric disorder, including severe major depressive disorder,
psychotic disorder and bipolar disorder or active substance
abuse as assessed by the Mini International Neuropsychiatric
Interview-Plus (M.I.N.I.-Plus); (2) severe suicidality, including
ideation, plan and intent; (3) presence of overt dementia;
(4) corticosteroid treatment during the previous 30 days; (5)
other serious medical disorders in addition to MS; (6) current
pregnancy.
Of the 627 patients with MS who were pre-screened using the
BDI-II, 462 did not satisfy the inclusion criteria and 75 refuse to
participate (Figure 1). The final sample consisted of 90 patients.
All patients were asked to invite a relative or caregiver to join
their treatment group; 19 relatives agreed to participate in the
treatment groups.
Patients and caregivers underwent three psychological
assessments by trained clinical psychologists who were blind to
group status: at baseline (T0), after the intervention (T1) and
6 months after the end of the intervention (follow-up, T2).
Measures
The three psychological assessments included the administration
of the following clinical interview and self-report questionnaires.
Fatigue Severity Scale (FSS)
This is a nine-item self-administered questionnaire, specifically
developed to assess the severity of fatigue in various situations
and to differentiate fatigue from clinical depression (Krupp et al.,
1989). Scores greater than 36 suggest the presence of severe
fatigue. The FSS has shown high Cronbach’s alpha values (0.84–
0.95) in patients with MS (Rosti-Otajärvi et al., 2017).
Beck Depression Inventory-II (BDI-II)
This is a 21-item self-report instrument that assesses the presence
and severity of depressive symptoms, based on the DSM-
IV criteria (Beck et al., 1996). Total score ranges from 0 to
63, with higher scores indicating higher levels of depressive
symptoms. The Consensus Group for Depression in MS
(Goldman Consensus Group, 2005) and the American Academy
of Neurology (Minden et al., 2014) consider the BDI-II (with a
cut-off score of 13) the best method of screening for depression
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FIGURE 1 | Participants flow diagram.
in MS patients. The internal consistency of the BDI-II is good to
excellent (α= 0.83–0.96) (Wang and Gorenstein, 2013).
Beck Anxiety Inventory (BAI)
This is a 21-item self-report measure with high internal
consistency (α = 0.92) that assesses the severity of cognitive,
somatic and affective anxiety symptoms (Beck et al., 1988; Beck
and Steer, 1993). Total score ranges from 0 to 63, with higher
scores indicating higher levels of anxiety. Scores higher than
9 suggest the presence of clinical anxiety (10-16: mild anxiety;
17-29: moderate anxiety; ≥30: severe anxiety).
Perceived Stress Scale (PSS)
This is a 10-item questionnaire measuring the extent to which the
respondent perceives his or her life situation as stressful (Cohen
et al., 1983). Higher scores indicate a higher level of stress. The
scale has shown an acceptable to excellent internal reliability
(α= 0.78–0.91) (Cohen and Janicki-Deverts, 2012).
Brief Illness Perception Questionnaire (B-IPQ)
This is a nine-item self-report questionnaire that assesses
emotional and cognitive representations of illness (Broadbent
et al., 2006). Higher scores indicate a more negative perception
of one’s illness. A recent systematic assessment of the reliability of
the B-IPQ confirmed that it has good psychometric properties,
including concurrent, predictive and discriminant validity
(Broadbent et al., 2015).
Functional Assessment of Multiple Sclerosis (FAMS)
This is a self-report scale designed to assess six aspects of quality
of life in patients with MS: Mobility, Symptoms, Emotional
Wellbeing, General Contentment, Thinking and Fatigue, and
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Family/Social Wellbeing (Cella et al., 1996). Higher scores
indicate better quality of life. The FAMS has good internal
consistency, with Cronbach’s alpha for the subscales ranging from
0.82 to 0.96 (Smith and Driskell, 2016).
Mini International Neuropsychiatric Interview-Plus
(M.I.N.I.-Plus)
This is a brief, structured diagnostic interview for the major
Axis I psychiatric disorders compatible with the Diagnostic and
Statistical Manual of Mental Disorders, 4th edition (DSM-IV)
criteria (Sheehan et al., 1998). The M.I.N.I.-Plus has shown good
inter-rater reliability and test–retest reliability (Sheehan et al.,
1998).
Caregivers were asked to complete the BDI-II and the BAI
to provide measures of their depressive and anxiety symptoms
respectively. They also completed the PSS and the WHO-
Quality of Life-Bref (WHOQOL-Bref; Murphy et al., 2000).
The WHOQOL-Bref consists of 26 questions, two assess overall
quality of life and the six relating to each of the following
four domains: physical; psychological; social relationships;
environment. The WHOQOL-Bref has shown good discriminant
validity, test–retest reliability and internal consistency (α= 0.65-
0.80) (De Girolamo et al., 2000).
Randomization and Blinding
Patients were randomly assigned into the two intervention
groups with a 1:1 ratio (45 in the BAI and 45 in the PEI
group), using a block-wise randomization sequence (block size
of 4 and 6). To ensure allocation concealment, the sequence was
determined by an independent researcher blind to the initial
assessment, using a random number generator1. To ensure the
blinding of the clinical psychologists performing the assessments,
the study coordinator communicated the treatment assignment
to each patient.
Because family members or caregivers joined the group to
which the corresponding patient had been randomly assigned it
was not possible to stratify this variable; however we expected that
the randomization of patients would ensure that participating
caregivers were randomly and evenly distributed across groups.
Intervention
The interventions were led by trained clinical psychologists
who were blind to the results of the baseline assessment. Both
interventions consisted of an 8-week group program, consisting
of weekly 3-h sessions.
Body-Affective Mindfulness (BAM) Intervention
The MBI used in this study is called body-affective mindfulness
(BAM); BAM is based on (1) awareness practices such as
body scan, breath meditation, walking meditation and yoga
exercises; (2) mindfulness in relationship practices such as
loving kindness, enriching listening to nature and persons
and self-compassion; (3) sensorimotor psychotherapy (Ogden
et al., 2006). Sensorimotor psychotherapy emphasizes the use of
somatic resources to attain and sustain a mindful disposition and
1www.randomizer.org
integrates the concept of a stress response with the concept of a
“window of tolerance” (Siegel, 2015), in order to maximize the
clinical utility of the intervention and tailor it to MS patients
(Keng et al., 2011). A more detailed description of the treatment
protocol has been provided elsewhere (Carletto et al., 2016).
In addition to the eight weekly sessions, the BAM intervention
also included an all-day (7-h) session and participants were
required to carry out daily 45-min homework assignments,
which consisted of mindfulness exercises and applications of
mindfulness to everyday life.
Psycho-Educational Intervention (PEI)
We used a control intervention based on that used by Grossman
et al. (2007) to control for the non-specific elements of the
BAM treatment. The PEI was based on a psycho-educational
framework and involved discussion of MS-related topics. The
group practiced relaxation techniques and gentle stretching
exercises at the end of each session. Participants were given
handouts covering the topics discussed and encouraged to
practice the exercises and techniques they had been shown as
homework. The PEI was conducted by a psychotherapist with
experience in relaxation training and in working with people
with MS and followed the same weekly format as the BAM
intervention, with the exception of the all-day session.
Statistical Analysis
Data were analyzed using the Statistical Package for Social
Science – Version 24 (SPSS-24; IBM SPSS Statistics for
Macintosh, Version 24.0. Armonk, NY, United States: IBM
Corp.).
Student’s t-test or the Mann–Whitney U test (where the
Kolmogorov–Smirnov test indicated that distribution departed
from normality) were used to analyze baseline group differences
in continuous measures and Fisher’s Exact Test was used for
categorical measures. The Mann–Whitney U test and Fisher’s
Exact Test were also used for within-group baseline comparisons
of the socio-demographic and clinical characteristics of
completers and drop-outs.
GLM repeated-measures ANOVAs were conducted to evaluate
the effects of group (BAM vs. PEI) and time (T0 vs. T1
vs. T2) and the time by group interaction, including only
patients who completed the entire clinical trial according to
the protocol [per-protocol (PP) analyses]. Mauchly’s test was
used to assess violations of the sphericity assumption and the
Greenhouse-Geisser correction was applied where necessary.
Repeated-measures ANOVA is quite robust against violations
of the assumptions of normality and sphericity (Stevens, 1986;
Berkovits et al., 2000). When the sphericity violation is only slight
(ε > 0.75) applying the Greenhouse-Geisser correction provides
a conservative assessment of differences (Berkovits et al., 2000).
Where significant effects were found, pairwise comparison
were carried out applying the Bonferroni correction. Results of
the post hoc comparison were presented as mean difference (MD)
with 95% confidence interval (CI) and standard error (SE).
Finally, we performed an exploratory ITT analysis to take into
account the missing data. All tests were two-sided and the level of
significance was set at p < 0.05.
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RESULTS
A flow diagram with the number of participants at each
assessment stage is presented in Figure 1. Ninety patients were
randomized: 45 were assigned to the BAM intervention and 45 to
the PEI.
Baseline Characteristics
There were no group differences in socio-demographic and
clinical characteristics at baseline (Tables 1, 2). Patients reported
moderate levels of depression and anxiety symptoms and high
levels of fatigue and of perceived stress. Our sample also had
generally negative illness representations and an unsatisfactory
quality of life (Table 2).
After group allocation 5 of 45 patients (11.1%) assigned to the
BAM and 3 of the 45 (6.7%) patients assigned to the PEI group
declined to participate (Figure 1). Of the 82 patients who began
the intervention, 4 (10%) (BAM) and 7 (16.7%) (PEI) failed to
complete the intervention.
A comparison of completers and drop-outs found no baseline
difference in the socio-demographical and clinical characteristics
of those assigned to BAM intervention. In the case of the PEI
group there were baseline differences between completers and
drop-outs with respect to BAI score (U = 82.5, p = 0.011), PSS
score (U = 89.5, p= 0.019) and Thinking and Fatigue subscale of
the FAMS score (U = 91.5, p = 0.027), with drop-outs having
lower anxiety [Mdn (IQR) = 9 (13) vs. 19.5 (19)] and lower
perceived stress [Mdn = 14 (13) vs. 25 (10)] than completers as
well as better quality of life in terms of the Thinking and Fatigue
subscale [Mdn (IQR)= 23.5 (8) vs. 19 (5.25)].
Per-protocol Analyses
We compared the impact of the interventions on the clinical
outcome variables in completers (BAM: N = 36; PEI: N = 35)
(Tables 3, 4).
Depressive Symptoms (Table 3)
There were group and time effects on BDI-II as well as a medium-
sized group by time interaction (p< 0.002; η2p = 0.09). Compared
with baseline, both interventions reduced depressive symptoms
at T1 (BAM: MD = 11.11, 95% CI: 8.17 – 14.57, SE = 1.2,
p < 0.001; PEI: MD = 5.11, 95% CI: 2.13 – 8.1, SE = 1.2,
p < 0.001). In both groups the improvement remained stable
at the follow-up (BAM: MD = 0.25, 95% CI: −2.49 – 2.99,
SE= 1.12, p= 1; PEI: MD= 1.4, 95% CI−1.38 – 4.18, SE= 1.13,
p = 0.66). However, pairwise comparison revealed that BAM
intervention was more effective than the PEI, at T1 (MD=−7.24,
95% CI: −12.02 – −2.45, SE = 2.4, p = 0.004) and at T2
(MD=−6.09, 95% CI:−10.61 –−1.57, SE= 2.27, p= 0.009).
Fatigue (Table 3)
There was no effect of time or group on FSS score, indicated that
neither intervention improved fatigue symptoms.
Anxiety Symptoms (Table 3)
There was a medium-sized main effect of time on BAI
score. Pairwise comparison confirmed an overall reduction in
symptoms between baseline and T1 (MD = 2.97, 95% CI:
0.120 – 5.83, SE = 1.16, p = 0.038), which remained stable
between T1 and T2 (MD = −1.19, 95% CI: −3.78 – 1.41,
SE = 1.06, p = 0.796). However, the BAM intervention was no
more effective than the PEI, i.e., there was no time by group
interaction.
Perceived Stress Symptoms (Table 3)
There was a medium-sized main effect of time on PSS score,
such that both interventions reduced perceived stress at T1
relative to baseline (MD = 3.71, 95% CI: 1.72 – 5.69, SE = 0.81,
p < 0.001). The reduction remained stable between T1 and T2
(MD = −1.22, 95% CI: −3.15 – 0.72, SE = 0.79, p = 0.380).
There was no main effect of group and no time by group
interaction.
Illness Perception (Table 3)
There were medium-sized main effects of time and group on
B-IPQ score. There was a time by group interaction, reflecting
the lack of change in perception of illness in the PEI group (T0
vs. T1: MD = 1.31, 95% CI: −1.71 – 4.34, SE = 1.23, p = 0.869;
T1 vs. T2: MD = −1, 95% CI −3.47 – 1.47, SE = 1, p = 0.969).
In contrast the BAM intervention improved B-IPQ score at T1
(MD = 4.89, 95% CI: 1.91 – 7.87, SE = 1.21, p < 0.001) and
this improvement that remain stable at T2 (MD = −0.03, 95%
CI −2.49 – 2.4, SE = 0.99, p = 1); in other words patients rated
their illness as less threatening after the BAM intervention than
at baseline.
Quality of Life (Table 4)
Repeated-measures ANOVA showed a medium-sized time by
group interaction size with respect to the total score of the FAMS.
The BAM intervention, but not the PEI, improved patients’
quality of life at T1 relative to baseline (MD = −10.14, 95% CI:
−16.19 – −4.09, SE = 2.47, p < 0.001) and this improvement
remained stable at T2 (MD = 0.62, 95% CI: −5.37 – 6.61,
SE= 2.44, p= 1).
There were time by group interactions with respect to scores
on the Symptoms, General Contentment, and Thinking and
Fatigue subscales, these effects ranged from medium to small in
size. Pairwise comparisons confirmed that the BAM intervention,
but not the PEI, led to improvements at T1 relative to baseline
(General Contentment: MD = −1.92, 95% CI: −3.39 – −0.44,
SE = 0.6, p = 0.006; Thinking and Fatigue: MD = −3.22,
95% CI: −5.48 – −0.97, SE = 0.92, p = 0.002), that were
maintained at T2 (General Contentment: MD = −0.33, 95%
CI: −1.75 – 1.09, SE = 0.58, p = 1; Thinking and Fatigue:
MD = 0.25, 95% CI: −1.73 – 2.23, SE = 0.81, p = 1). In the
case of the Symptoms subscale pairwise comparisons revealed no
differences.
There was a main effect of group on Mobility subscale
score, with higher scores overall in the BAM group than the
PEI group (MD = 3.06, 95% CI: −3.39 – −0.44, SE = 1.2,
p = 0.013). Finally, there were medium-sized main effects
of time and group on Emotional Wellbeing subscale scores.
Pairwise comparisons showed that overall emotional wellbeing
was better in the BAM group than the PEI group (MD = 3.6,
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TABLE 1 | Demographic and clinical characteristics of randomized multiple sclerosis patients in the two intervention groups.
BAM (N = 45) PEI (N = 45) Test p
Mean (SD)/Median (IQR) Mean (SD)/Median (IQR)
Age 44.1 (9.4) 45.1 (9.3) t(88) = −0.496 0.621a
Years of education 13 (2) 13 (5) U = 899 0.340b
Time since diagnosis 9 (10) 7 (7) U = 885 0.303b
EDSS 2 (1) 2.5 (2.3) U = 806 0.127b
N (%) N (%)
Sex 1c
M 13 (28.9) 13 (28.9)
F 32 (71.1) 32 (71.1)
Marital status 0.739c
Single 15 (33.3) 12 (26.7)
Married 23 (51.1) 24 (53.3)
Divorced 7 (15.6) 9 (20)
Employment status 0.503c
Unemployed 13 (28.9) 17 (37.8)
Employed 31 (68.9) 28 (62.2)
Student 1 (2.2) 0 (0)
MS type 0.663c
Relapsing-remitting 38 (88.4) 36 (8%)
Primary progressive 1 (2.3) 1 (2.2)
Secondary progressive 3 (7) 4 (8.9)
Progressive relapsing 1 (2.3) 4 (8.9)
Pharmacological treatment 36 (80) 36 (80) 1c
at-test; bMann–Whitney U test; cFisher Exact test. MS, multiple sclerosis; EDSS, Expanded Disability Status Scale.
TABLE 2 | Comparison of clinical outcome measures at baseline between multiple sclerosis patients randomized in the two intervention groups.
BAM (N = 45) PEI (N = 45)
T0 T0 Test p
FSS 50 (17) 51 (23) U = 995 0.888b
Above cut-off 35 (77.8%) 33 (73.3%) X2(1) = 0.241 0.807c
BDI-II 19 (11) 20 (10) U = 887 0.310b
Above cut-off 45 (100%) 45 (100%)
BAI 15 (17) 17 (18) U = 919.5 0.453b
Above cut-off 32 (71.1%) 33 (73.3%) X2(1) = 0.055 1c
PSS 25 (7) 24 (31) U = 889 0.318b
B-IPQ 49.42 (8.83) 51.69 (9.72) t(88) = −1.16 0.25a
FAMS
Total score 109.6 (25.5) 104.2 (23.5) t(87) = 1.02 0.309a
Mobility 20 (9) 16.5 (7) U = 849 0.246b
Symptoms 19.33 (4.95) 19.81 (5.34) t(87) = −0.434 0.665a
Emotional wellbeing 19.83 (7) 18 (6.75) U = 818.5 0.158b
General contentment 14.44 (5.79) 13.48 (4.98) t(87) = 0.845 0.401a
Thinking and fatigue 21 (10.5) 20.5 (6) U = 914.5 0.535b
Family/Social wellbeing 17.73 (4.63) 16.22 (6.16) t(79.8) = 1.3 0.196a
Additional concerns 33.95 (7.13) 32.46 (7.54) t(87) = 0.956 0.342a
at-test; bMann–Whitney U test; cFisher Exact test. Mean (SD), Median (IQR), or N(%) are shown, accordingly. FSS, Fatigue Severity Scale; BDI-II, Beck Depression
Inventory-II; BAI, Beck Anxiety Inventory; PSS, Perceived Stress Scale; B-IPQ, Illness Perception Questionnaire-Brief; FAMS, Functional Assessment of Multiple Sclerosis.
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TABLE 3 | Repeated measures ANOVA on multiple sclerosis patients’ clinical outcome measures (per-protocol analyses).
T0 T1 T2 F p η2p
FSS BAM 46.25 (11.55) 40.92 (13.46) 41.61 (13.46) Time: F (2,138) = 2.21 0.113 0.031
PEI 45.23 (15.46) 45.51 (12.21) 45.69 (14.53) Group: F (1,69) = 0.81 0.373 0.012
T × G: F (2,138) = 7.93 0.057 0.041
BDI-II BAM 21.39 (7.38) 10.28 (9.05) 10.03 (7.42) Time: F (2,138) = 64.43 <0.001 0.487
PEI 22.63 (7.36) 17.51 (11.08) 16.11 (11.32) Group: F (1,69) = 6.45 0.013 0.086
T × G: F (2,138) = 6.79 0.002 0.090
BAI BAM 17.06 (11.09) 14.19 (11.84) 16.17 (10.18) Time: F (2,138) = 3.46 0.034 0.048
PEI 20.8 (11.43) 17.71 (10.94) 18.11 (10.84) Group: F (1,69) = 1.82 0.181 0.026
T × G: F (2,138) = 0.37 0.692 0.005
PSS BAM 23.92 (6.83) 18.33 (7.68) 20.19 (7.3) Time: F (2,138) = 10.79 <0.001 0.135
PEI 24.2 (7.28) 22.37 (5.89) 22.94 (6.94) Group: F (1,69) = 2.94 0.091 0.041
T × G: F (2,138) = 2.75 0.067 0.038
B-IPQ BAM 49.81 (9.04) 44.92 (9.48) 44.94 (9.59) Time: F (1.77,122.2) = 7.54 0.001 0.098
PEI 51.86 (10.34) 50.54 (10.51) 51.54 (10.02) Group: F (1,69) = 5.06 0.028 0.068
T × G: F (1.77,122.17) = 30.91 0.027 0.054
T × G, time by group interaction effect. FSS, Fatigue Severity Scale; BDI-II, Beck Depression Inventory-II; BAI, Beck Anxiety Inventory; PSS, Perceived Stress Scale;
B-IPQ, Illness Perception Questionnaire-Brief.
TABLE 4 | Repeated measures ANOVA on multiple sclerosis patients’ quality of life assessed with the Functional Assessment of Multiple Sclerosis
questionnaire (per-protocol analyses).
T0 T1 T2 F p η2p
Total score BAM 110.9 (23.61) 121 (25.76) 120.4 (24.17) Time: F (2,136) = 3.25 0.042 0.046
PEI 101.3 (24.42) 101.5 (25.55) 97.35 (25.04) Group: F (1,68) = 10.32 0.002 0.132
T × G: F (2,136) = 7.63 0.001 0.101
Mobility BAM 18.31 (5.64) 19.19 (5.53) 18.86 (5.67) Time: F (2,136) = 0.55 0.579 0.008
PEI 16.28 (5.38) 15.92 (5.26) 15.16 (5.21) Group: F (1,68) = 6.5 0.013 0.087
T × G: F (2,136) = 2.12 0.125 0.030
Symptoms BAM 19.33 (4.34) 20.33 (4.43) 20.5 (4.13) Time: F (2,136) = 0.19 0.831 0.003
PEI 19.57 (5.33) 18.27 (5.21) 18.35 (5.86) Group: F (1,68) = 1.67 0.200 0.024
T × G: F (2,136) = 5.5 0.005 0.075
Emotional wellbeing BAM 19.69 (5.38) 22.31 (5.24) 21.94 (5.69) Time: F (1.76,120.1) = 7.68 0.001 0.101
PEI 17.09 (5.41) 18.57 (5.58) 17.71 (5.91) Group: F (1,68) = 9.3 0.003 0.120
T × G:F(1.76,120.1) = 1.44 0.241 0.021
General contentment BAM 14.86 (6.07) 16.78 (5.75) 17.11 (5.67) Time: F (1.74,118.4) = 3.54 0.038 0.049
PEI 13.09 (5.05) 13.63 (5.33) 12.71 (4.77) Group: F (1,68) = 6.88 0.011 0.092
T × G: F (1.74,118.38) = 3.93 0.027 0.055
Thinking and fatigue BAM 20.81 (7.31) 24.03 (7.16) 23.78 (5.81) Time: F (2,136) = 2.60 0.078 0.037
PEI 19.33 (6.80) 19.11 (7.91) 18.43 (7.88) Group: F (1,68) = 6.72 0.012 0.090
T × G: F (2,136) = 6.51 0.020 0.087
Family/social wellbeing BAM 17.89 (4.48) 18.39 (5.35) 18.22 (4.51) Time: F (2,136) = 0.87 0.423 0.013
PEI 15.97 (6.47) 16.01 (6.11) 15 (6.18) Group: F (1,68) = 4.17 0.050 0.058
T × G: F (2,136) = 1.13 0.326 0.016
Additional concerns BAM 33.91 (7.37) 35.36 (8.53) 34.81 (7.93) Time: F (2,136) = 0.36 0.700 0.005
PEI 32.31 (8.16) 31.66 (8.74) 32.6 (8.45) Group: F (1,68) = 2.25 0.138 0.032
T × G: F (2,136) = 1.67 0.191 0.024
T × G, time by group interaction effect.
95% CI: 1.24 – 5.95, SE = 1.18, p = 0.003). There were
also overall increases in scores between baseline and T1
(MD = −1.94, 95% CI: −3.09 – −0.8, SE = 0.47, p < 0.001),
suggesting that both groups showed improvements in emotional
wellbeing.
Psychopathology
At baseline the results of the M.I.N.I.-Plus suggested that
adjustment disorders (BAM: 47.2%; PEI: 28.6%), anxiety
disorders (including generalized anxiety disorders, panic
disorders, phobia, etc.) (BAM: 33.3%; PEI: 20%) and major
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depressive episode (BAM: 30.6%; PEI: 37.1%) were prevalent in
both groups. The proportion of participants no longer meeting
the criteria for these disorders after the intervention was higher
in the BAM group than the PEI group (see Supplementary
Table 1).
ITT Analyses (Table 5)
An ITT analysis was also performed on the whole randomized
sample. Only two patients (they were amongst those who
declined to participate in the BAM group) refused to complete the
T1 and T2 assessments. In the case of these two patients baseline
data were substituted for the missing T1 and T2 data. The results
generally confirmed the PP findings on the effectiveness of the
BAM, especially with regard to quality of life (FAMS). In the ITT
analyses the time by group interaction for BDI-II score was no
longer significant (p= 0.061), although in descriptive terms it was
only the BAM group which had a mean score below the threshold
after the intervention. The ITT analyses did show, however, a
main effect of time on FSS score [F(2,176) = 4.6, p = 0.011;
η2p = 0.050], reflecting an overall reduction in fatigue between
baseline and T1 (MD = 3.06, 95% CI: 0.386 – 5.73, SE = 1.1,
p = 0.019). In the ITT analysis of illness perception there was no
longer a time by group interaction. There was, however, a time by
group interaction with respect to PSS score reflecting a reduction
in perceived stress symptoms relative to baseline in the BAM
group both at T1 (MD = 5.49, 95% CI: 2.91 – 8.07, SE = 1.06,
TABLE 5 | Repeated measures ANOVA on the entire randomized multiple sclerosis patients (ITT analyses).
T0 T1 T2 F p η2p
FSS BAM 46.62 (10.91) 41.53 (12.79) 42.2 (12.75) Time: F (2,176) = 4.6 0.011 0.050
PEI 45.38 (14.93) 44.36 (13.02) 44.84 (14.83) Group: F (1,88) = 0.31 0.577 0.004
T × G: F (2,176) = 2.3 0.103 0.026
BDI-II BAM 20.91 (7.41) 11.71 (9.84) 11.47 (9.50) Time: F (1.81,158.9) = 65.6 <0.001 0.427
PEI 21.64 (7.06) 16.22 (10.45) 14.6 (10.79) Group: F (1,88) = 2.6 0.111 0.029
T × G: F (1.81,158.9) = 2.94 0.061 0.032
BAI BAM 16.71 (10.93) 14.31 (12.13) 15.31 (10.19) Time: F (2,176) = 2.15 0.119 0.024
PEI 18.56 (11.34) 17.16 (10.94) 16.67 (10.27) Group: F (1,88) = 1 0.319 0.011
T × G: F (2,176) = 0.29 0.747 0.003
PSS BAM 23.89 (6.8) 18.4 (7.77) 19.71 (7.52) Time: F (2,176) = 11 <0.001 0.111
PEI 22.69 (7.64) 21.4 (6.39) 21.89 (7.03) Group: F (1,88) = 1.12 0.292 0.013
T × G: F (2,176) = 4.43 0.013 0.048
B-IPQ BAM 49.42 (8.83) 45.58 (9.45) 44.96 (9.31) Time: F (1.73,152.2) = 8.95 <0.001 0.092
PEI 51.69 (9.72) 49.71 (10.05) 50.82 (9.40) Group: F (1,88) = 5.21 0.025 0.056
T × G: F (1.73,152.2) = 2.78 0.073 0.031
FAMS
Total score BAM 109.6 (25.5) 119.3 (28.30) 119.1 (27.1) Time: F (2,174) = 5.54 0.005 0.060
PEI 104.2 (23.50) 105.7 (24.80) 103.3 (26.4) Group: F (1,87) = 5.24 0.025 0.057
T × G: F (2,174) = 5.76 0.004 0.062
Mobility BAM 17.87 (6.01) 18.67 (5.84) 18.16 (6.09) Time: F (2,174) = 0.52 0.593 0.006
PEI 17.01 (5.50) 16.34 (5.26) 16.07 (5.6) Group: F (1,87) = 2.51 0.117 0.028
T × G: F (2,174) = 2.59 0.078 0.029
Symptoms BAM 19.33 (4.95) 20.29 (5.04) 20.87 (4.62) Time: F (2,174) = 0.33 0.722 0.004
PEI 19.81 (5.34) 18.94 (5.31) 18.77 (5.82) Group: F (1,87) = 1.02 0.315 0.012
T × G: F (2,174) = 6.71 0.002 0.072
Emotional wellbeing BAM 19.13 (5.38) 21.65 (5.72) 21.53 (5.88) Time: F (1.75,151.9) = 11.21 <0.001 0.114
PEI 17.36 (5.54) 19.2 (5.43) 18.3 (5.62) Group: F (1,87) = 5.78 0.018 0.062
T × G: F (1.75,151.9) = 1.22 0.294 0.014
General contentment BAM 14.44 (5.79) 16.36 (5.87) 16.62 (5.98) Time: F (1.67,145.4) = 6.02 0.005 0.065
PEI 13.48 (4.98) 14.24 (5.34) 13.95 (5.33) Group: F (1,87) = 3.27 0.074 0.036
T × G: F (1.67,145.4) = 1.95 0.153 0.022
Thinking and fatigue BAM 21.07 (7.63) 24.04 (7.93) 23.93 (6.6) Time: F (2,174) = 4.39 0.014 0.048
PEI 20.37 (6.77) 20.16 (7.92) 20.33 (8.32) Group: F (1,87) = 3.44 0.067 0.038
T × G: F (2,174) = 5.21 0.006 0.057
Family/Social Well-Being BAM 17.73 (4.63) 18.24 (5.10) 17.96 (4.88) Time: F (2,174) = 0.89 0.413 0.010
PEI 16.22 (6.16) 16.54 (5.92) 15.84 (5.98) Group: F (1,87) = 2.77 0.100 0.031
T × G: F (2,174) = 0.31 0.737 0.004
Additional Concerns BAM 33.95 (7.13) 35.04 (8.63) 35.07 (7.94) Time: F (1.87,162.9) = 1.06 0.346 0.012
PEI 32.46 (7.54) 32.62 (8.15) 33.21 (7.8) Group: F (1,87) = 1.85 0.178 0.021
T × G: F (1.87,162.9) = 0.50 0.597 0.006
T × G, time by group interaction effect; FSS, Fatigue Severity Scale; BDI-II, Beck Depression Inventory-II; BAI, Beck Anxiety Inventory; PSS, Perceived Stress Scale;
B-IPQ, Illness Perception Questionnaire-Brief; FAMS, Functional Assessment of Multiple Sclerosis.
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p< 0.001) and at T2 (MD= 4.18, 95% CI: 1.44 – 6.92, SE= 1.12,
p= 0.001).
Caregivers
Nineteen caregivers agreed to participate in the same
intervention group as the patient for whom they cared
(BAM n = 9; PEI: n = 10). Half the participating caregivers
(50%) were the mothers of MS patients (see Supplementary
Table 2 for further details). One caregiver dropped out after
the baseline assessment and another dropped out during the
intervention phase. Due to the low number of caregivers that
agreed to participate we were unable to evaluate the effects of the
interventions on this population.
DISCUSSION
To the best of our knowledge, this is the first RCT to evaluate the
effectiveness of a group-based MBI in MS patients with depressive
symptoms by comparing it with a control intervention. In
MS depression is one of the main determinants of patients’
quality of life. It can increase fatigue and further compromise
cognitive function and may also have a negative impact on
relationships and reduce adherence to medication (Feinstein,
2011). For these reasons the Goldman Consensus Conference
(Goldman Consensus Group, 2005) and the American Academy
of Neurology (Minden et al., 2014) have highlighted the
importance of diagnosing and treating depression in people
with MS.
Mindfulness-based interventions are a relatively brief and
cost-effective psychological treatment that have been shown to
reduce depressive symptoms and improve quality of life in
patients with several chronic diseases (Hofmann et al., 2010;
Crowe et al., 2016; Veehof et al., 2016; Haller et al., 2017). Recent
systematic reviews concluded that MBIs could also help patients
with MS, by reducing the mental (such as anxiety and depression)
and physical (i.e., fatigue) symptoms and improving the patients’
quality of life (Simpson et al., 2014; Levin et al., 2014; San José
et al., 2016). However, none of these studies compared MBIs with
an active control, which means that there are question marks over
the specificity of the efficacy of MBIs.
When only patients who completed the interventions are
considered, our RCT data indicate that the BAM intervention was
more effective in reducing symptoms of depression (as measured
by the BDI-II) than the PEI. Although both groups showed
improvements in BDI-II score after the intervention and at the
follow-up assessment, the BAM had lower BDI-II scores; this was
a medium-sized effect. This finding extends previous research
showing that in MS patients MBIs are effective when compared
with standard care (Mills and Allen, 2000; Grossman et al., 2010;
Tavee et al., 2011), by showing that a MBI was more effective
than a psycho-educational intervention in reducing symptoms
of depression. In the ITT analysis only the main effect of time
remained statistically significant, weakening the evidence for the
superior efficacy of the BAM intervention relative to the PEI.
However, given that depressive symptoms can remit or reduce
spontaneously (Posternak and Miller, 2001), it is possible that this
occurred in the patients who dropped out, reducing the difference
between the two interventions and masking the superior efficacy
of the BAM that was found in the PP analysis. It should be noted
that in both the PP and ITT analyses, the BAM group’s mean BDI-
II score was below the threshold after the intervention, indicating
the BAM intervention had a clinically meaningful impact on
depressive symptoms.
The BAM-induced reduction in depressive symptoms as
assessed by the BDI-II, which is a self-report measure, was
replicated in the results from the semi-structured clinical
interview (M.I.N.I.-Plus). Previous studies have relied on self-
report outcome measures (Levin et al., 2014; Simpson et al., 2014)
and no previous studies have evaluated psychosocial functioning
before and after an intervention using objective measures. The
M.I.N.I.-Plus data confirmed that in the BAM group there was
a reduction in the number of patients currently experiencing
a major depressive episode or adjustment disorders after the
intervention. The M.I.N.I.-Plus also showed a reduction in the
number of patients in the BAM group who met the criteria for an
anxiety disorder (generalized anxiety disorder, panic disorders or
specific phobia). At the baseline assessment both groups reported
mild to moderate levels of anxiety, in addition to high perceived
stress.
The BAM intervention was no more effective than the PEI
in reducing anxiety symptoms and perceived stress, according
to the self-report data (BAI and PSS). Both treatments reduced
symptoms and the effects were maintained at the follow-up
assessment, suggesting that they were similarly effective in
producing long-term improvements in these domains.
A recent review indicated that relative to no treatment or
control treatments such as standard care or walking in the garden,
MBIs have a positive impact on fatigue in neurological conditions
such as stroke, traumatic brain injury and MS (Ulrichsen et al.,
2016). In our study the BAM and PEI interventions were not
effective (PP analysis) or only similarly effective (ITT analysis)
in reducing fatigue. Further research into this area is needed.
After receiving a diagnosis of illness, individuals develop an
organized pattern of cognitive and emotional representations of
their own illness, which can be referred to as an illness perception
(Petrie and Weinman, 2006). These beliefs can influence coping
behavior (Leventhal et al., 1984), with negative illness perceptions
being associated with poorer recovery and increased healthcare
use, even after controlling for objective illness severity (Leventhal
et al., 1984; Petrie and Weinman, 2006). Our PEI was not effective
in modifying MS patients’ illness perception, whereas patients in
the BAM group reported less negative illness perceptions after
the intervention, suggesting that the intervention had promoted
a positive reorganization of their cognitive and emotional illness
representations. A change in illness perceptions can help to
reduce everyday disability and improve functioning and quality
of life (Petrie and Weinman, 2006).
Mindfulness-based interventions have been shown to
enhance quality of life in many different chronic conditions
(Demarzo et al., 2015; Crowe et al., 2016; Veehof et al., 2016;
Haller et al., 2017) and we confirmed this with respect to
MS in our study. We found that the BAM intervention was
effective in improving patients’ overall quality of life, whereas
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the PEI was not. Furthermore, the improvement seen in the
BAM group was maintained 6 months after the intervention
had ended, suggesting that the BAM intervention induces
long-term modifications in quality of life. In particular, the
BAM intervention reduced problems with concentration,
thinking and fatigue and improved scores on the general
contentment subscale, which deals with satisfaction and
acceptance of health-related quality of life. The only quality
of life domain to show improvement in the PEI group was
emotional wellbeing, and the BAM group showed a similar
improvement.
Mindfulness-based interventions have been shown to have a
low attrition rate and no side effects (Grossman et al., 2010;
Simpson et al., 2014). In our study the two interventions had
comparable attrition rates. Eight patients dropped out after group
allocation (5 from the BAM group; 3 from the PEI group)
and 11 patients dropped out during the treatment (3 from the
BAM group; 7 from the PEI group). The majority of the latter
category dropped out due for logistic or work-related reasons.
Although the attrition rate was close to the acceptable threshold,
which is 20% of randomized participants (Schulz and Grimes,
2002), the only baseline differences between completers and
dropouts, were lower levels of anxiety and perceived stress in
patients that dropped out of the PEI. Furthermore, only 4% of
patients allocated to the BAM group refused to complete the
post-treatment assessments, which allowed us to perform an ITT
analysis.
Our study has some important limitations. One was the
failure to recruit sufficient caregivers. Caregivers of patients
with MS experience the stress and difficulties related to the
management of a relative with a chronic disabling disease.
Furthermore, patients’ depression has a negative impact on
the quality of life and mood of their caregivers (Giordano
et al., 2012). We were therefore interested in evaluating whether
caregivers would benefit from the treatment. Unfortunately,
we were unable to recruit and retain sufficient caregivers to
warrant statistical analysis of their data. Another limitation is
that owing to the characteristics of the intervention, which
requires at least partially preserved mobility, we had to exclude
severely disabled patients. Similarly, the high rate of refusal
to participate in the study (45% of patients that fulfilled the
criteria declined to participate) and the high dropout rate may
be at least partially explained by logistic factors. The CReSM
Unit is the regional reference center for MS, and thus patients
travel to the center from a wide area. Mobility difficulties may
have prevented or discouraged MS patients living further from
the center from participating in the interventions. In view of
the apparent efficacy of MBIs in MS patients it is therefore
essential to develop new ways of delivering mindfulness-based
protocols, such as eHealth programs, to render them more
accessible.
In conclusion, this study is, to the best of our knowledge, the
first RCT to compare the effectiveness of a MBI and psycho-
educational intervention in MS patients. Other strengths of
the study in addition to the use of an active control group
are the focus on symptoms of depression and the use of a
clinical interview to corroborate self-report data on psychological
functioning. The results on completers strengthen the evidence
that MBIs reduce depressive symptoms and enhance quality
of life in patients with MS (Levin et al., 2014; Simpson
et al., 2014; San José et al., 2016) as they demonstrate the
effects of MBIs are specific to this type of intervention and
are not the result of non-specific factors. Furthermore, the
BAM intervention was shown to be effective in reducing
negative representations of the illness, modulating cognitive and
emotional aspects of illness perception and enhancing acceptance
of the pathology. The BAM intervention also led to a reduction
in anxiety symptoms and perceived stress, although it was no
more effective in these respects than the PEI. This finding is
not surprising, given that the BAM protocol was specifically
tailored to manage depression. All the improvements observed
immediately after the BAM intervention were maintained at
the long-term follow-up assessment thus providing further
supporting for the effectiveness of the BAM intervention in MS
patients.
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